Michael DeLuca
Executive Vice President of Global Medical Affairs & Medical Information
专长:
Mike currently serves as Senior Vice President of Medical affairs at EVERSANA. With 20+ years of healthcare and pharmaceutical industry experience in multiple leadership roles, he holds extensive experience in medical information, medical communications, medical affairs operations, and supporting the medical review of promotional and non-promotional materials. Mike has supported the launch of 10 new products while working at multiple pharmaceutical companies and has expertise across multiple therapeutic areas, including rare disease. Mike is also a Board Member of phactMI.
Articles by Michael DeLuca
The Evolving Landscape of HCP Engagement and the Role of Medical Information in This Era of Digital Innovation
This poster delves into the dynamic landscape of HCP engagement and the pivotal role of Medical Information (MI). It underscores the significance of effective HCP engagement for enhancing clinical decision-making and patient outcomes and emphasizes the cruciality of access to short, reliable, and personalized content across diverse digital channels and independent websites. To address these […]
Considerations for the Development of Interactive / Innovative Medical Information Content – Insights from a Service Provider
The creation of high-quality, customer-centric medical information (MI) content accessible through various data dissemination channels is crucial. EVERSANA, a provider of global MI contact center services, has embarked on developing more interactive MI content. This initiative involves converting traditional SRDs and FAQs into engaging and innovative formats by identifying considerations essential for this format of […]
Current Trends in Medical Review of Promotional and Non-Promotional Materials
Medical Information (MI) plays a crucial role in addressing inquiries from healthcare professionals, payors, and patients/caregivers and ensuring pharmaceutical products’ safe, effective, and appropriate use. However, MI teams often have other important responsibilities beyond the scope of traditional MI services. EVERSANA conducted a survey in 2023 to assess current trends and to better understand Medical […]
Considerations for Globalization of Medical Information Services: A Service Partner Perspective
This poster details the considerations for globalizing medical information (MI) services. Traditionally, pharmaceutical companies began in one geographical region before expanding, but evolving regulations and research priorities for rare diseases, oncology/hematology, immunology, and cell and gene therapy have led to simultaneous global regulatory filings. To streamline operations and maintain control, these companies partner with global […]
Significance of Promotional and Non-Promotional Materials Review Support Services
Importance of a Well-Defined Medical Legal Regulatory Review Process It is critical for companies to have a well-defined medical, legal and regulatory review process. One of the predominant challenges companies face is that medical and regulatory reviewers often have multiple competing responsibilities. Additionally, the volumes of materials required for review can fluctuate and be significant, […]
Patient-centric Approach to Clinical Trial Support Leveraging Medical Information Services
The number of clinical studies conducted has steadily shown a significant increase year over year for the past two decades. However, the number of new drug and biologic approvals have not seen this same kind of increase. This causes several challenges for manufacturers such as increased competition and difficulty recruiting patients, particularly for rare diseases, […]
Value Proposition of Medical Information Services: Current Perspectives from the Industry
Medical Information (MI) is an important customer facing function of pharmaceutical companies that plays a crucial role in addressing inquiries from healthcare professionals, payors, and patients and caregivers and ensuring pharmaceutical products’ safe and effective use. However, demonstrating the value of MI both internally and externally can be a challenge for many pharmaceutical company MI […]